Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast

Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness, if left untreated. DME treatments include the anti-VEGFs Eylea, Lucentis, and off-label Avastin. Other approved agents for this indication are the long-acting corticosteroid implants Ozurdex and Iluvien, and the anti-VEGF / Ang-2 bispecific antibody Vabysmo; Beovu also got a label expansion for DME, and upon FDA approval in August 2023, high-dose aflibercept (Eylea HD) was added to the treatment armamentarium. Of note, Lucentis 0.3 mg, Eylea, and Eylea HD are also approved for all forms of DR without DME in the United States, whereas Lucentis 0.5 mg is approved for DR in Europe. Competition will increase in the DR / DME market with the launch of ranibizumab (Lucentis) and aflibercept (Eylea) biosimilars and with the potential approval of key emerging therapies such as Roche’s ranibizumab port delivery system (Susvimo), promising longer dosing intervals. Non-IVT agents like Oculis’s OCS-01, a topical eye drop formulation of dexamethasone, will likely constitute a paradigm shift and may revolutionize the management of DME patients in the future.

​​​QUESTIONS ANSWERED

• How large is the treatable DR / DME population, and how will diagnosis / drug-treatment rates change over time?
• Do KOLs perceive any differences between Avastin, Eylea, Beovu, Lucentis, and Vabysmo? How is the use of these drugs expected to change over the next 10 years as agents with distinct MOAs and ROAs enter the market? How are the corticosteroid implants Iluvien and Ozurdex being used to treat DME?
• How will Vabysmo, Eylea HD, and emerging therapies such as the ranibizumab port delivery system capitalize on the need for therapies with longer dosing schedules than those currently available in the market?
• How will market dynamics be impacted by the launch of biosimilars of Lucentis and Eylea?
• How have Lucentis and Eylea been incorporated into the treatment algorithm for DR exclusive of DME in the United States? What will be the impact of Eylea HD and of Beovu if it is successfully launched for PDR?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continuous updates in 2023 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with thought-leading retinal specialists and supported by survey data collected for this and other Clarivate research.

Epidemiology: Prevalence of severe NPDR, PDR, and DME, by country, including diagnosed / drug-treated populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key DR and DME therapies through 2032, segmented by brands / biosimilars and generics and epidemiological subpopulations.

Emerging therapies: Phase 3 / PR: 4 drugs; Phase 2: 10 drugs.